Efficiency of Retinoprotective Dry AMD Therapy with Neuroprotective Therapy: a Randomized Clinical Trials Meta-analysis

Article retracted.

Рurpose. А meta-analysis of randomized clinical trials of efficiency and safety of retinalamin water-soluble polypeptide retinal fractions
complex neuroprotective therapy in patients with dry age-related macular degeneration (amd), conducted in russia. Мethods. Published results of various clinical trials were searched by a single investigator using the “scientific electronic library” (elibrary.ru). meta-analysis included all clinical trials of retinalamin efficacy, where its route of administration and dosage corresponded with the guidelines for medical use of retinalamin in patients with dry amd. Results. Primary search revealed 320 publications concerning retinalamin. 11 of those presented results of randomized clinical trial that satisfied the requirements, and hence were included into the meta-analysis. beside the parabulbar and intramuscular administration, prescribed officially, retinalamin was also administered subconjunctivally, with electrophoresis and with subcutaneous injections in temporal zone. in three studies the observation period is 3 months, in one study it is 5 months, in four studies it is 6 months, and in two studies it is 12 months. in the rest of studies the observation period is less than 3 months. all the studies present the changes in visual acuity right after the therapy course. meta-analysis revealed a statistically significant visual acuity improvement, best discernible in patients with areds 3 amd stage up to 6 months after retinalamin treatment. the positive dynamics in visual acuity changing persists during the first 3 months. repeated
therapy courses in 3–6 months provided further progress. perimetry revealed the increasing of visual field borders and decreasing
of central scotomae amount and area; the findings have also improved after the repeated course. the electrophysiology studying
showed the positive dynamics as well and correlated with visual acuity changes. optical coherence tomography, blood flow examination and a series of other tests were also used. however, varying diagnostic methods in different trials as well as a low level of statistical data processing, impeded the fulfillment of a comprehensive analysis. Conclusion. Randomized clinical trial meta-analysis proved the efficacy of retinalamin therapy in patients with dry amd

1. Cheung L.K., Eaton A. Age-related macular degeneration. Pharmacotherapy. 2013;33(8):838–855. DOI: 10.1002/phar.1264

2. Pascolini D., Mariotti S.P. Global estimates of visual impairment: 2010. The British journal of ophthalmology. 2012;96(5):614–618. DOI: 10.1136/bjophthalmol-2011-300539

3. J. S. Epidemiology of age-related macular degeneration. Retina 3rd edition Schachat AP, Ryan S, editors St Louis (MO): Mosby. 2001. 1039–1050.

4. Curcio C.A., Millican C.L., Allen K.A., Kalina R.E. Aging of the human photoreceptor mosaic: evidence for selective vulnerability of rods in central retina. Investigative Ophthalmology & Visual Science. 1993;34(12):3278–3296.

5. Feeney-Burns L., Burns R.P., Gao C.L. Age-related macular changes in humans over 90 years old. American Journal of Ophthalmology. 1990;109(3):265–278.

6. Feeney-Burns L., Berman E.R., Rothman H. Lipofuscin of human retinal pigment epithelium. American Journal of Ophthalmology. 1980;90(6):783–791.

7. Laatikainen L., Larinkari J. Capillary-free area of the fovea with advancing age. Investigative Ophthalmology & Visual Science. 1977;16(12):1154–1157.

8. Age-Related Eye Disease Study Research G. The Age-Related Eye Disease Study (AREDS): design implications. AREDS report no. 1. Controlled Clinical Trials. 1999;20(6):573–600.

9. Shintani T., Klionsky D.J. Autophagy in health and disease: a double-edged sword. Science. 2004;306(5698):990–995. DOI: 10.1126/science.1099993

10. Nussenblatt R.B., Ferris F., 3rd. Age-related macular degeneration and the immune response: implications for therapy. American Journal of Ophthalmology. 2007;144(4):618–626. DOI: 10.1016/j.ajo.2007.06.025

11. Age-Related Eye Disease Study Research G. Risk factors associated with agerelated macular degeneration. A case-control study in the age-related eye disease study: Age-Related Eye Disease Study Report Number 3. Ophthalmology. 2000;107(12):2224–2232.

12. Hyman L., Schachat A.P., He Q., Leske M.C. Hypertension, cardiovascular disease, and age-related macular degeneration. Age-Related Macular Degeneration Risk Factors Study Group. Archives of Ophthalmology. 2000;118(3):351–358.

13. Klein R., Klein B.E., Tomany S.C., Cruickshanks K.J. The association of cardiovascular disease with the long-term incidence of age-related maculopathy: the Beaver Dam Eye Study. Ophthalmology. 2003;110(6):1273–1280. DOI: 10.1016/S0161-6420(03)00599-2

14. van Leeuwen R., Ikram M.K., Vingerling J.R., Witteman J.C., Hofman A., de Jong P.T. Blood pressure, atherosclerosis, and the incidence of age-related maculopathy: the Rotterdam Study. Investigative Ophthalmology & Visual Science. 2003;44(9):3771–3777.

15. Klein R., Klein B.E., Franke T. The relationship of cardiovascular disease and its risk factors to age-related maculopathy. The Beaver Dam Eye Study. Ophthalmology. 1993;100(3):406–414.

16. Vinding T. Age-related macular degeneration. An epidemiological study of 1000 elderly individuals. With reference to prevalence, funduscopic findings, visual impairment and risk factors. Acta Ophthalmologica Scandinavica Supplement. 1995;217:1–32.

17. Vingerling J.R., Dielemans I., Bots M.L., Hofman A., Grobbee D.E., de Jong P.T. Age-related macular degeneration is associated with atherosclerosis. The Rotterdam Study. American Journal of Epidemiology. 1995;142(4):404–409.

18. Age-Related Eye Disease Study Research G. A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no.8. Archives of Ophthalmology. 2001;119(10):1417–1436.

19. Age-Related Eye Disease Study 2 Research G. Lutein + zeaxanthin and omega-3 fatty acids for age-related macular degeneration: the Age-Related Eye Disease Study 2 (AREDS2) randomized clinical trial. JAMA. 2013;309(19):2005–2015. DOI: 10.1001/jama.2013.4997

20. Evans J.R., Lawrenson J.G. Antioxidant vitamin and mineral supplements for slowing the progression of age-related macular degeneration. The Cochrane Database of Systematic Reviews. 2017;7:CD000254. DOI: 10.1002/14651858. CD000254.pub4

21. Lawrenson J.G., Evans J.R. Omega 3 fatty acids for preventing or slowing the progression of age-related macular degeneration. The Cochrane Database of Systematic Reviews. 2015;4:CD010015. DOI: 10.1002/14651858.CD010015.pub3

22. Егоров Е.А., Оганезова Ж.Г., Егорова Т.Е. Возможности применения Ретиналамина в терапии дистрофических заболеваний глаза (обзор клинических исследований). РМЖ Клиническая офтальмология. 2009;10(2):57–58. [Egorov E.A., Oganezova Zh.G., Egorova T.E. Possibilities of Retinalamin usage in treatment of dystrophic eye diseases (literary review). RMJ Clinical Ophthalmology=RMJ Klinicheskaya Oftal’mologiya. 2009;10(2):57–58. (in Russ.)]

23. Измайлов А.С. Возрастная макулярная дегенерация. Лечение сухой формы ВМД. РМЖ Клиническая офтальмология. 2014;14(1):10–14. [Izmailov A.S. Agerelated macular degeneration. Treatment of the dry form of AMD. Russian Medical Journal. Clinical ophthalmology=Rossiyskiy meditsinskiy zhurnal. Klinicheskaya Oftal’mologiya. 2014;14(1):10–14. (in Russ.)]

24. Нероев В.В., Зайцева О.В. Обзор научных исследований эффективности Ретиналамина® при возрастной макулярной дегенерации. Российский офтальмологический журнал. 2015;(4):79–82. [Neroev V.V., Zaitseva O.V. Investigations in the Effectiveness of Retinalamin in Age-Related Macular Degeneration Therapy: a Review. Russian Ophthalmological Journal=Rossiyskiy Oftal’mologicheskiy Zhurnal. 2015;(4):79–82. (in Russ.)]

25. Подгорная Н.Н. Современные возможности лечения возрастной макулярной дегенерации сетчатки. Клиническая геронтология. 2015;(1–2):48–53. [Podgornaya N.N. Contemporary potentials for the treatment of age-related macular degeneration. Clinical gerontology=Klinicheskaya Gerontologiya. 2015;21(1–2):48–53. (in Russ.)]

26. Астахов Ю.С., Кирьянова В.В., Максимов А.В., Морозова Н.В., Соколов В.О., Флоренцева С.С. Оптимизация лечения сухой формы возрастной макулярной дегенерации методом электроназального электрофореза препаратом «Ретиналамин». Офтальмологические ведомости. 2010;3(1):68–77. [Astakhov Yu.S., Kir’yanova V.V., Maksimov A.V., Morozova N.V., Sokolov V.O., Florentseva S.S. The treatment optimisation of the dry form of are-related macular degeneration by means of “Retinalamin” preparation endonasal electrophoresis. Ophthalmologic vedomosti=Oftalmologicheskie Vedomosti 2010;3(1):68–77. (in Russ.)]

27. Гао Ц., Федорищева Л.Е. Результаты медикаментозного лечения больных с возрастной макулодистрофией по материалам глазной клиники Саратовского государственного медицинского университета. Саратовский научно-медицинский журнал. 2008;3(21):68–72. [Gao J., Fedorischeva L.E. Results of drug therapy of patients with age-related macular degeneration on materials of eye clinic of Saratov State Medical University. Saratov journal of medical scientific research=Saratovskiy nauchno-meditsinskiy zhurnal. 2008;3(21):68–72. (in Russ.)]

28. Дунаева М.В. Коллагенопластика с ретиналамином в лечении возрастной макулодистрофии. Новости медицины и фармации. 2011;417:29–35. [Dunaeva M.V. Retinolamin collagenoplastics in age-related macular degeneration treatment. Novosti meditsini i farmatsii=Novosti Meditsiny i Farmatsii. 2011;417:29–35. (in Russ.)]

29. Егоров Е.А. Опыт применения Ретиналамина при различных офтальмологических заболеваниях. РМЖ Клиническая офтальмология. 2017;1:35–38. [Egorov E.A. Retinalamin for varios ophthalmic disorders: clinical experience. RMJ Clinical Ophthalmology=RMJ Klinicheskaya Oftal’mologiya. 2017;1:35–38. (in Russ.)]. DOI: 10.21689/2311-7729-2017-17-1-35-38

30. Коротких С.А., Борзунов О.И., Бирюкова Г.Л., Бобыкин Е.В. Оценка продолжительности эффекта антидистрофической терапии при возрастной макулярной дегенерации. Уральский медицинский журнал. 2014;1(115):11–15. [Korotkikh S.A., Borzunov O.I., Birukova G.L., Bobykin E.V. Evaluation of the effectiveness of age macular degeneration treatment. Ural Medical Journal=Uralskiy Meditsinskiy Zhurnal. 2014;1(115):11–15. (in Russ.)].

31. Морозова Н.В., Новиков Д.П., Соколов В.О., Флоренцева С.С. Эффективность лечения возрастной макулярной дегенерации, сухой формы методом эндоназального электрофореза препарата «Ретиналамин». Офтальмологические ведомости. 2009;2(1):51–56. [Morozova N.V., Novikov D.P., Sokolov V.O., Florentseva S.S. The efficacy of age-related macular degeneration, dry form, treated with “Retinalamin” endonasal electrophoresis. Ophthalmologic vedomosti=Oftalmologicheskie Vedomosti. 2009;2(1):51–56. (in Russ.)]

32. Нероев В.В., Зайцева О.В., Охоцимская Т.Д., Цапенко И.В., Лантух Е.П. Эффективность Ретиналамина® у пациентов с сухой формой возрастной макулярной дегенерации при различной кратности курсов внутримышечных инъекций. Российский офтальмологический журнал. 2016;1:39–46. [Neroev V.V., Zaitseva O.V., Okhotsimskaya T.D., Tsapenko I.V., Lantukh E.P. The Effectiveness of Retinalamin® Administered by Various Intramuscular Injection Timings in the Treatment of Patients with the Dry Form of AgeRelated Macular Degeneration. Russian Ophthalmological Journal=Rossiyskiy Oftal’mologicheskiy Zhurnal. 2016;1:39–46. (in Russ.)]

33. Трофимова С.В., Хлудиева Т.А., Ивко О.М., Анас А.-Д. Влияние биорегулирующей терапии на качество жизни людей пожилого возраста с ретинальной патологией. Успехи геронтологии. 2006;18:96–99. [Trofimova S.V., Khludieva T.A., Ivko O.M., Anas A.-D. The impact of bioregulating therapy on the quality of life of elderly patients suffering from retinal degeneration. Advances in gerontology=Uspekhi Gerontologii. 2006;18:96–99. (in Russ.)]

34. Федотова Т.С., Хокканен В.М., Трофимова С.В. Применение комплекса пептидных биорегуляторов у пациентов с полиморфизмом генов CFH и ARMS2. Медицинский вестник Башкорстана. 2016;11(1(61):40–43. [Fedotova T.S., Khokkanen V.M., Trofimova S.V. The application of a complex of peptide bioregulators in patients with polymorphism of genes CFH and ARMS2. Bashkorstan Medical Journal=Meditsinskiy Vestnik Bashkorstana. 2016;11(1(61):40–43. (in Russ.)]

35. Хавинсон В.Х., Трофимова С.В., Горбунов А.В., Осокина Ю.Ю. Современные аспекты терапии возрастной макулярной дистрофии у лиц пожилого и старческого возраста. Научные ведомости Белгородского государственного университета. Серия Медицина, Фармация. 2011;22(117):57–62. [Khavinson V.Kh., Trofimova S.V., Gorbunov A.V., Osokina Yu.Yu. Modern aspects of therapy of agerelated macular degeneration in elderly and senile age. Belgorod State University Scientific Bulletin. Medicine, Pharmacy=Nauchnie vedomosti Belgorodskogo gosudarstvennogo universiteta. Seriya Meditsina, Farmatsiya. 2011;22(117):57–62. (in Russ.)]

36. Хасанова Н.Х., Беляева А.В. Результаты применения Ретиналамина при заболеваниях сетчатки. РМЖ Клиническая офтальмология. 2008;9(3):77–82. [Khasanova N.Kh., Belyaeva A.V. Results of Retinalamin usage in retinal diseases. Russian Medical Journal. Clinical ophthalmology=Rossiyskiy Meditsinskiy Zhurnal. Klinicheskaya Oftal’mologiya. 2008;9(3):77–82. (in Russ.)]